Medtech company NeurAxis upsizes IPO and lowers price to $6 a share vs. $8 previously

NeurAxis, a medical technology company with an FDA-approved therapy to treat abdominal pain associated with IBS in adolescents aged 11 to 18 years old, tweaked the terms of its initial public offering on Friday. In a filing with the Securities and Exchange Commission, the company said it now plans to offer 1.7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares.

7 million shares priced at $6 each, while selling shareholders will offer 2.8 million shares. The company previously planned to offer 937,500 shares priced at $8, with selling shareholders to offer 1.8 million shares. The company has applied to list on the New York Stock Exchange under the ticker ‘NRXS.’ Alexander Capital L.P. is sole underwriter on the deal.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surgeThe results come amid investor anxiety over the thousands of lawsuits claiming that J&J's talc-based baby powder and other products caused cancer.
Source: CNBC - 🏆 12. / 72 Read more »

Oddity stock soars out of the gate, opens 39% above the IPO priceOddity Tech Ltd. received an ovation on its Wall Street debut Wednesday, as the Israel-based consumer technology platform for the beauty and wellness...
Source: MarketWatch - 🏆 3. / 97 Read more »

Advanced Biomed sets IPO terms, which could value the biotech at up to $625 millionAdvanced Biomed Inc. has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to...
Source: MarketWatch - 🏆 3. / 97 Read more »